Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
Cancer therapy has entered a new era, transitioning from unspecific chemotherapeutic agents to increasingly specific immune-based therapeutic strategies. Among these, chimeric antigen receptor (CAR) T cells have shown unparalleled therapeutic potential in treating refractory hematological malignanci...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-05-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/8/5/472 |
| _version_ | 1797708198381092864 |
|---|---|
| author | Stefan Stoiber Bruno L. Cadilha Mohamed-Reda Benmebarek Stefanie Lesch Stefan Endres Sebastian Kobold |
| author_facet | Stefan Stoiber Bruno L. Cadilha Mohamed-Reda Benmebarek Stefanie Lesch Stefan Endres Sebastian Kobold |
| author_sort | Stefan Stoiber |
| collection | DOAJ |
| description | Cancer therapy has entered a new era, transitioning from unspecific chemotherapeutic agents to increasingly specific immune-based therapeutic strategies. Among these, chimeric antigen receptor (CAR) T cells have shown unparalleled therapeutic potential in treating refractory hematological malignancies. In contrast, solid tumors pose a much greater challenge to CAR T cell therapy, which has yet to be overcome. As this novel therapeutic modality matures, increasing effort is being invested to determine the optimal structure and properties of CARs to facilitate the transition from empirical testing to the rational design of CAR T cells. In this review, we highlight how individual CAR domains contribute to the success and failure of this promising treatment modality and provide an insight into the most notable advances in the field of CAR T cell engineering. |
| first_indexed | 2024-03-12T06:17:48Z |
| format | Article |
| id | doaj.art-8d8cb47f66f840919738e444baa51cae |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-12T06:17:48Z |
| publishDate | 2019-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-8d8cb47f66f840919738e444baa51cae2023-09-03T02:24:55ZengMDPI AGCells2073-44092019-05-018547210.3390/cells8050472cells8050472Limitations in the Design of Chimeric Antigen Receptors for Cancer TherapyStefan Stoiber0Bruno L. Cadilha1Mohamed-Reda Benmebarek2Stefanie Lesch3Stefan Endres4Sebastian Kobold5Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Member of the German Center for Lung Research (DZL), 80337 Munich, GermanyCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Member of the German Center for Lung Research (DZL), 80337 Munich, GermanyCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Member of the German Center for Lung Research (DZL), 80337 Munich, GermanyCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Member of the German Center for Lung Research (DZL), 80337 Munich, GermanyCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Member of the German Center for Lung Research (DZL), 80337 Munich, GermanyCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Member of the German Center for Lung Research (DZL), 80337 Munich, GermanyCancer therapy has entered a new era, transitioning from unspecific chemotherapeutic agents to increasingly specific immune-based therapeutic strategies. Among these, chimeric antigen receptor (CAR) T cells have shown unparalleled therapeutic potential in treating refractory hematological malignancies. In contrast, solid tumors pose a much greater challenge to CAR T cell therapy, which has yet to be overcome. As this novel therapeutic modality matures, increasing effort is being invested to determine the optimal structure and properties of CARs to facilitate the transition from empirical testing to the rational design of CAR T cells. In this review, we highlight how individual CAR domains contribute to the success and failure of this promising treatment modality and provide an insight into the most notable advances in the field of CAR T cell engineering.https://www.mdpi.com/2073-4409/8/5/472CAR T cellchimeric antigen receptorimmunotherapyadoptive cell therapy |
| spellingShingle | Stefan Stoiber Bruno L. Cadilha Mohamed-Reda Benmebarek Stefanie Lesch Stefan Endres Sebastian Kobold Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy Cells CAR T cell chimeric antigen receptor immunotherapy adoptive cell therapy |
| title | Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy |
| title_full | Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy |
| title_fullStr | Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy |
| title_full_unstemmed | Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy |
| title_short | Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy |
| title_sort | limitations in the design of chimeric antigen receptors for cancer therapy |
| topic | CAR T cell chimeric antigen receptor immunotherapy adoptive cell therapy |
| url | https://www.mdpi.com/2073-4409/8/5/472 |
| work_keys_str_mv | AT stefanstoiber limitationsinthedesignofchimericantigenreceptorsforcancertherapy AT brunolcadilha limitationsinthedesignofchimericantigenreceptorsforcancertherapy AT mohamedredabenmebarek limitationsinthedesignofchimericantigenreceptorsforcancertherapy AT stefanielesch limitationsinthedesignofchimericantigenreceptorsforcancertherapy AT stefanendres limitationsinthedesignofchimericantigenreceptorsforcancertherapy AT sebastiankobold limitationsinthedesignofchimericantigenreceptorsforcancertherapy |